La vendita allo scoperto per Sezzle dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Sezzle. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Sezzle (NASDAQ:SEZL) Azioni, Report sulle vendite allo scoperto

SEZZLE INC

Sezzle

Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.

Jim Cramer

Tech

ACHR

ANET

CSCO

CSGP

RKLB

SEZL

VNOM

Da &#34;Mad Money&#34;, il confronto tra Arista e Cisco. Inoltre, le sue call su Archer, UTI, Sezzle, Rocket Lab, CoStar, Viper e Fiserv.

Jim Cramer dice no a questo titolo e ne consiglia uno più economico

Waste Management: 16%

Long Ideas

News

Markets

Media

L&#39;analista di CNBC esprime grande fiducia in un titolo, mentre un&#39;altra azienda non riceve il suo benestare. Scopri di chi si tratta.

Jim Cramer dice sì: &#34;Strong Buy&#34; è un&#39;opportunità da non perdere?

Short Ideas

Pre-Market Outlook

Trading Ideas

Brighthouse Financial, Inc. - Common Stock

Ignorare questi segnali d&#39;allarme può costare caro? Analisi di tre titoli e strategie per proteggere il proprio portafoglio.

3 titoli che potrebbero crollare: cosa fare prima che sia troppo tardi

Sezzle Inc

KVC Behavioral Healthcare Kentucky And Valvoline Partner To Expand Suicide Prevention Efforts Across The Commonwealth Of Kentucky

Rockwell Automation Launches EtherNet/IP In-cabinet Solution to Help Manufacturers Build Smarter, More Efficient Panels

Jefferies analyst Omar Nokta maintains Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) with a Buy and maintains $5 price target.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Safe Bulkers, Maintains $5 Price Target

PLUG

Plug Power Says GenEco Electrolyzers Go Live At The Green Box In Netherlands Showcasing Real-World Performance For European Customers

ProPetro Holding Corp. ("ProPetro" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) is pleased to announce that its PROPWR℠ division has secured its inaugural contract under which it will commit 80 megawatts of power generation capacity. This 10-year agreement represents a significant milestone for PROPWR, marking its first customer commitment and aligning with the Company's mission to "Rethink The Grid."
Executed in collaboration with a Permian-focused E&amp;P operator, the project involves PROPWR committing capacity of 80 megawatts, with asset deployment scheduled to begin in the third quarter of this year and continuing through 2026. PROPWR will deliver turnkey power to a distributed microgrid installation, utilizing in-field gas where utility power is unavailable to support production operations. This solution combines natural gas reciprocating engines and gas turbine generation to provide reliable power services under the contract. The comprehensive scope of service includes assets, onsite operations, maintenance, monitoring, an availability guarantee, and take-or-pay obligations for the customer supporting PROPWR's capacity commitment. This agreement not only underscores PROPWR's commitment to innovation and growth but also lays the groundwork for future expansion, with customer options to substantially increase PROPWR's committed capacity over time.
The Company is actively pursuing additional opportunities, and is engaged in negotiations for additional contracts that extend beyond today's announcement. As highlighted during the Company's first-quarter earnings call, PROPWR has already agreed to terms with one additional customer through a letter of intent and is working to finalize the associated contract. The Company anticipates sharing more exciting contract announcements in the near future.

PUMP

ProPetro Holding's PROPWR Division Secures 10-Yr Contract For 80 Megawatts Of Power Generation Capacity

ASPI

ASP Isotopes Enters Agreement Relating To Potential Acquisition Of Renergen Limited, With Goal Of Combined Group Expected To Be Accretive To 2026 Adj. EPS And Generate Over $300M EBITDA In 2030; Says Transaction 'has received irrevocable support from over 35% of Renergen shareholders and is expected to close during the third quarter of 2025 ahead of the planned QLE spin out.'

Mirion Technologies Announces Proposed $300M Private Offering Of Convertible Senior Notes Due 2030 With Option For Additional $45M

Telsey Advisory Group analyst Dana Telsey maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $43 price target.

BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $43 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $30 price target.

Reiteration

NTLA

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and maintains $1.5 price target.

D. Boral Capital Maintains Buy on PEDEVCO, Maintains $1.5 Price Target

QBTS

D-Wave Launches Commercial-Grade Advantage2 Quantum System To Tackle Complex Problems In Optimization, AI And Materials Simulation

Biotech

General

TRVI

Trevi Therapeutics Presents Additional Analyses From Phase 2a RIVER Trial At American Thoracic Society 2025 International Conference

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 -
- Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting eligibility for Priority Review; the BTD request was based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response -
- Biologics License Application (BLA) submission for veligrotug is on track for second half 2025 -
- Actively preparing organization for planned U.S. commercial launch in 2026 -
Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug ("veli"), an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye.
The THRIVE phase 3 clinical trial in active TED evaluated 5 infusions of veli or placebo every three weeks with primary topline analysis at week 15 and then followed patients through week 52.

VRDN

Viridian Therapeutics Announces Positive Long-Term Durability Data From THRIVE Phase 3 Clinical Trial Of Veligrotug In TED Patients

Toolstation Selects GXO As Logistics Partner In The Netherlands

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and lowers the price target from $8 to $3.

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $3

-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis –
-- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases –
-- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway –
-- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation in IBD --
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jpUKFDUv9SBOaAYEuDBVLMrIuE8vmhtiOpWfbossUQvn_ZgVR_ZhWKlfdYagPXw3J_EzkmVJYc5JjZ7ZCkYRpRxCeF1prBNvXpoYxY6gplo=">Pasithea Therapeutics Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced new preclinical data demonstrating that PAS-004 provides superior inhibition of ETS2-driven inflammatory responses compared to selumetinib in a human macrophage model of chronic inflammation that mimics the inflammatory milieu seen in inflammatory bowel disease (IBD).
This study was conducted at the Francis Crick Institute in London, U.K. by Dr. James Lee, a gastroenterologist and Clinician Scientist Group Leader at the Genetic Mechanisms of Disease Laboratory. Dr. Lee was the lead author of a landmark 2024 Nature paper that identified ETS2 as a master regulator of inflammatory responses in IBD, and uncovered a novel genetic mechanism behind the disease, which pointed to a new, potentially effective treatment strategy through MEK inhibition.
In this new study RNA sequencing was used to measure gene expression, with PAS-004 consistently outperforming the FDA-approved MEK inhibitor selumetinib across all tested doses (0.01 μM, 0.1 μM, and 1 μM), showing greater downregulation of ETS2 target genes, as well as experimentally validated MEK1/2 pathway genes. These data suggest more robust and durable MEK inhibition by PAS-004 under inflammatory conditions.

KTTA

Pasithea Therapeutics' New Preclinical Data Shows PAS-004 Provides Superior Inhibition Of ETS2-Driven Inflammatory Responses Compared To Selumetinib In Human Macrophage Model Of Chronic Inflammation In IBD

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) affirms FY2025 sales outlook from $2.00 million-$5.00 million to $2.00 million-$5.00 million.

Guidance

ARBE

Arbe Robotics Affirms FY2025 Sales Guidance of $2.00M-$5.00M

Autozi Regains Nasdaq Compliance As Share Price Meets $1.00 Minimum Bid Requirement Over 14 Consecutive Trading Days

Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) reported quarterly losses of $(0.09) per share. This is a 35.71 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $40.00 thousand which missed the analyst consensus estimate of $100.00 thousand by 60.00 percent. This is a 70.80 percent decrease over sales of $137.00 thousand the same period last year.

Earnings

Earnings Misses

Arbe Robotics Q1 Adj. EPS $(0.09) Up From $(0.14) YoY, Sales $40.00K Miss $100.00K Estimate

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) sees Q2 sales of $7.000 million-$7.100 million vs $7.17 million analyst estimate.

CRGO

Freightos Sees Q2 Sales $7.000M-$7.100M vs $7.17M Est

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sezzle Inc. - SEZL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sezzle Inc. - SEZL

Sezzle to Announce Fourth Quarter 2024 Results and Participate in Upcoming Investor Conferences

Sezzle Reports Fourth Quarter and Fiscal Year 2024 Results

Sezzle Announces Six-for-One Stock Split and $50 Million Stock Repurchase Program

Sezzle Redefines the Shopping Experience with New Features for Smarter Spending

Sezzle to Announce First Quarter 2025 Results and Participate in Upcoming Investor Conferences

Sezzle to Hold an Annual Shareholder Meeting, Report 1Q25 Results, and Attend Investor Conferences

Comments

Sezzle

Vendite allo scoperto

Sezzle (NASDAQ:SEZL) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO